This article originally appeared at https://pubmed.ncbi.nlm.nih.gov/37196452/
Authors Silvia Kochen 1 , Manuela Villanueva 1 , Liliana Bayarres 1 , Anilu Daza-Restrepo 1 , Silvia Gonzalez Martinez 1 , Silvia Oddo 2
- PMID: 37196452
- DOI: 10.1016/j.yebeh.2023.109210
Highlights
- •Prospective observational open study of treatment with cannabidiol for 6 months.
- •Efficacy: 86% responders, 11% non-responders, and 2% worsening.
- •Dose: The responding patients ended with a mean of 329 mg/day.
- •Adverse events: 34% of patients reported mild adverse events and no patient reported severe adverse effects.
- •Most patients have a significant improvement in their quality of life.
Abstract
Cannabidiol oil (CBD) has been approved as an anti-seizure medication for the treatment of uncommon types of epilepsy, occurring in children: Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. There are few publications in relation to use the CBD in adult patients with focal drug-resistant epilepsy. The objective of this study was to evaluate the efficacy, tolerability, safety, and quality of life, of adjuvant treatment with CBD, in adult patients with drug-resistant focal epilepsy for at least 6 months.
An open, observational, prospective cohort study was conducted using a before-after design (time series) in adult patients undergoing outpatient follow-up in a public hospital in Buenos Aires, Argentina.
From a total of 44 patients, 5% of patients were seizure-free, 32% of patients reduced more than 80% of their seizures and 87% of patients reduced 50% of their monthly seizures. Eleven percent presented a decrease of less than 50% in seizure frequency.
The average final dose was 335 mg/d orally administered. Thirty-four percent of patients reported mild adverse events and no patient reported severe adverse effects. At the end of the study, we found in most patients a significant improvement in the quality of life, in all the items evaluated.
Adjuvant treatment with CBD in adult patients with drug-resistant focal epilepsy was effective, safe, well tolerated, and associated with a significant improvement in their quality of life.
References
- Li H-L. The origin and use of cannabis in eastern Asia linguistic-cultural szaimplications. Economic Botany 1974;28(3):293–301. McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol 2018;5(9):1077–88.View in Article
- Mechoulam R.
- Carlini E.A.
- Carlini E.A.
- Leite J.R.
- Tannhauser M.
- Berardi A.C.
- Izquierdo I, Nasello AG. Effects of cannabidiol and of diphenylhydantoin on the hippocampus and on learning. Psychopharmacologia [Internet] 1973;31(2):167–75. Available from: https://pubmed.ncbi.nlm.nih.gov/4578907.View in Article
- Matsuda L.A.
- Lolait S.J.
- Brownstein M.J.
- Young A.C.
- Bonner T.I.
- Devane W.A.
- Hanus L.
- Breuer A.
- Pertwee R.G.
- Stevenson L.A.
- Griffin G.
- et al.
- Fiore M.
- Pereira P.
- World Health Organization 2020. UN Commission on Narcotic Drugs reclassifies cannabis to recognize its therapeutic uses. https://www.who.int/news/item/04-12-2020-un-commission-on-narcotic-drugs-reclassifies-cannabis-to-recognize-its-therapeutic-uses.View in Article
- Kochen S, Cannabis medicinal, Editorial. Salud Colectiva, Universidad Nacional de Lanús, 2022. ISSN 1669-2381 | EISSN 1851-8265 | doi: 10.18294/sc..3991.View in Article
- Kwan P.
- Arzimanoglou A.
- Berg A.T.
- Brodie M.J.
- Hauser W.A.
- Mathern G.
- et al.
- Chen Z.
- Brodie M.J.
- Liew D.
- Kwan P.
- Franco V.
- Perucca E.
- EMA 2019: https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex.View in Article
- FDA 2018: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms.View in Article
- FDA 2022: https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare.View in Article
- Gaston T, Szaflarski JP. Cannabis for the Treatment of Epilepsy: an Update. Curr Neurol Neurosci Rep 2018;18(11).View in Article
- Devinsky O.
- Marsh E.
- Friedman D.
- Thiele E.
- Laux L.
- Sullivan J.
- et al.
- Devinsky O.
- Cross J.H.
- Laux L.
- Marsh E.
- Miller I.
- Nabbout R.
- et al.
- Miller I.
- Scheffer I.E.
- Gunning B.
- Sanchez-Carpintero R.
- Gil-Nagel A.
- Perry M.S.
- et al.
- Devinsky O.
- Patel A.D.
- Cross J.H.
- Villanueva V.
- Wirrell E.C.
- Privitera M.
- et al.
- Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. GWPCARE4 Study Group, 2018 17. Cannabidiol in patients with seizures associated with Lennox-.View in Article
- Thiele E.A.
- Bebin E.M.
- Filloux F.
- Kwan P.
- Loftus R.
- Sahebkar F.
- et al.
- Lattanzi S.
- Trinka E.
- Striano P.
- Rocchi C.
- Salvemini S.
- Silvestrini M.
- et al.
- Carlson M.D.A.
- Morrison R.S.
- Bosdriesz J.R.
- Stel V.S.
- van Diepen M.
- Meuleman Y.
- Dekker F.W.
- Zoccali C.
- et al.
- Metelli S.
- Chaimani A.
- Rosenberg E.C.
- Louik J.
- Conway E.
- Devinsky O.
- Friedman D.
- Devinsky O.
- Verducci C.
- Thiele E.A.
- Laux L.C.
- Patel A.D.
- Filloux F.
- et al.
- Szaflarski J.P.
- Bebin E.M.
- Comi A.M.
- Patel A.D.
- Joshi C.
- Checketts D.
- et al.
- Kochen S.
- Manin A.
- Montiel R.
- Devinsky O.
- Cilio M.R.
- Cross H.
- Fernandez-Ruiz J.
- French J.
- Hill C.
- et al.
- Szaflarski J.P.
- Devinsky O.
- Lopez M.
- Park Y.D.
- Zentil P.P.
- Patel A.D.
- et al.
- Hausman-Kedem M.
- Menascu S.
- Kramer U.
- Pesántez Ríos G.
- Armijos Acurio L.
- Jimbo Sotomayor R.
- Cueva V.
- Pesántez Ríos X.
- Navarrete Zambrano H.
- et al.
- Caraballo R.
- Reyes G.
- Demirdjian G.
- Huaman M.
- Gutierrez R.
- Cunha J.M.
- Carlini E.A.
- Pereira A.E.
- Ramos O.L.
- Pimentel C.
- Gagliardi R.
- et al.
- Nenert R.
- Allendorfer J.B.
- Bebin M.
- Gaston T.E.
- Grayson L.E.
- Houston J.T.
- et al.
- Billakota S.
- Devinsky O.
- Marsh E.
- Perucca E.
- Huestis M.A.
- Solimini R.
- Pichini S.
- Pacifici R.
- Carlier J.
- Busardò F.P.
- Von Wrede R.
- Helmstaedter C.
- Surges R.
Article info
Publication history
Published online: May 15, 2023
Accepted: April 1, 2023
Received in revised form: March 30, 2023
Received: February 27, 2023
